Add Formweb to your mobile device
System Formulary Update
Cabenuva Extended Release Injectable
Situation
Formulary addition of Cabenuva (cabotegravir and rilpivirine extended release injectable suspension) was approved at the December 2021 System Pharmacy and Therapeutics Committee meeting.
Background
Cabenuva is a long-acting injectable suspension for the treatment of HIV-1 in adult patients who have achieved viral suppression (HIV RNA <50 copies/mL) on a standard, 3-drug HIV-1 regimen. It is given a sequential, intramuscular injections to the ventrogluteal site.
Dosing is cabotegravir 600 mg/rilpivirine 900 mg (6 mL total) x1, followed by cabotegravir 400 mg/rilpivirine 600 mg (4 mL total) every 28 days. See Prescribing information for details.
Assessment/Recommendations
Changes Effective: Tuesday, January 18, 2022
System P&T voted to include the following products on the UNC Health System Drug Formulary:
- CABENUVA (cabotegravir 600 mg [200 mg/3 mL] and rilpivirine 900 mg [300 mg/3mL]) Initiation Kit (NDC 49702-240-15)
- CABENUVA (cabotegravir 400 mg [200 mg/2 mL] and rilpivirine 600 mg [300 mg/2mL]) Maintenance Kit (NDC 49702-253-15)